A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
A phase 3 trial testing Sasanlimab in bladder & urothelial cancer, active and no longer recruiting.
Overview
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT04165317, led by Pfizer, and active but no longer recruiting when checked on 2026-09-11. Official title: A Phase 3, Multinational, Randomised, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer or PF-06801591 as a Single Agent in Participants With BCG-Unresponsive NMIBC. Planned enrolment is 1068 participants (actual). The study started in 2019-12-30 and primary completion is expected in 2024-12-02. Results have been posted on ClinicalTrials.gov; they are not yet summarised here.
Similar pages
not linked directly; found by shared links- TrialSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialSymbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialA Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Shares Bladder & urothelial cancer and the tag ctgov-ingest.